ǿմý

Skip to main content

U.S. FDA approves a second Alzheimer's drug that can modestly slow disease

The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday, July 2, 2024 for mild or early cases of dementia caused by Alzheimer’s. (Eli Lilly and Company via AP) The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday, July 2, 2024 for mild or early cases of dementia caused by Alzheimer’s. (Eli Lilly and Company via AP)
Share
WASHINGTON -

U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.

The U.S. Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown to delay cognitive decline in patients, following last year’s approval of a similar drug from Japanese drugmaker Eisai.

The delay seen with both drugs amounts to a matter of months — about seven months, in the case of Lilly’s drug. Patients and their families will have to weigh that benefit against the downsides, including regular IV infusions and potentially dangerous side effects like brain swelling.

Physicians who treat Alzheimer’s say the approval is an important step after decades of failed experimental treatments.

“I’m thrilled to have different options to help my patients,” said Dr. Suzanne Schindler, a neurologist at Washington University in St. Louis. “It’s been difficult as a dementia specialist — I diagnose my patients with Alzheimer’s and then every year I see them get worse and they progress until they die.”

Both Kisunla and the Japanese drug, Leqembi, are laboratory-made antibodies, administered by IV, that target one contributor to Alzheimer's — sticky amyloid plaque buildup in the brain. Questions remain about which patients should get the drugs and how long they might benefit.

The new drug's approval was expected after an outside panel of FDA advisors unanimously voted in favor of its benefits at a public meeting last month. That endorsement came despite several questions from FDA reviewers about how Lilly studied the drug, including allowing patients to discontinue treatment after their plaque reached very low levels.

Costs will vary by patient, based on how long they take the drug, Lilly said. The company also said a year’s worth of therapy would cost US$32,000 — higher than the US$26,500 price of a year’s worth of Leqembi.

The FDA’s prescribing information tells doctors they can consider stopping the drug after confirming via brain scans that patients have minimal plaque.

The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22 per cent more slowly in terms of memory and cognitive ability than those who received a dummy infusion.

The main safety issue was brain swelling and bleeding, a problem common to all plaque-targeting drugs. The rates reported in Lilly's study — including 20 per cent of patients with microbleeds — were slightly higher than those reported with competitor Leqembi. However, the two drugs were tested in slightly different types of patients, which experts say makes it difficult to compare the drugs' safety.

Kisunla is infused once a month compared to Leqembi’s twice-a-month regimen, which could make things easier for caregivers who bring their loved ones to a hospital or clinic for treatment.

“Certainly getting an infusion once a month is more appealing than getting it every two weeks,” Schindler said.

Lilly's drug has another potential advantage: Patients can stop taking it if they respond well.

In the company’s study, patients were taken off Kisunla once their brain plaque reached low levels. Discontinuing the drug could reduce the costs and safety risks of long-term use. It's not yet clear when patients might need to resume infusions.

Logistical hurdles, spotty insurance coverage and financial concerns have all slowed the rollout of competitor Leqembi, which Eisai co-markets with U.S. partner Biogen. Many smaller hospitals and health systems aren’t yet setup to prescribe the new plaque-targeting Alzheimer's drugs.

First, doctors need to confirm that patients with dementia have the brain plaque targeted by the new drugs. Then they need to find a drug infusion center where patients can receive therapy. Meanwhile, nurses and other staff must be trained to perform repeated scans to check for brain swelling or bleeding.

“Those are all things a physician has to have set up," said Dr. Mark Mintun, who heads Lilly’s neuroscience division. "Until they get used to them, a patient who comes into their office will not be offered this therapy.” 

CTVNews.ca ǿմý

An Ottawa woman, who has survived cancer and has overcome addiction, has won $70 million with Lotto Max.

An eight-year-old boy from Los Angeles had his vacation to Montreal include a dramatic moment when a creature swimming underwater bit him causing a bloody scene at Jean Dore beach.

Liberal MP Anthony Housefather says he is 'looking forward to making a real difference' as the government's new special adviser on Jewish community relations and antisemitism.

Local Spotlight

Adam finds out how a giant tortoise walking along a sidewalk is inspiring a woman visiting from Australia.

A wrestling fan from Guelph, Ont. thought he was down for the count after winning tickets to a “once-in-a-lifetime” WWE event in Toronto.

Lacey may look like just another pet chicken on Emily Carrington’s B.C. property. But she has a title her coop mates don’t: Guinness World Record holder.

Philip Kim, who competes as "B-Boy Phil Wizard," is set to make Canadian sports history this summer as the country's first-ever Olympic breaking athlete.

A new documentary filmed in Nova Scotia by marine biologist and veterinarian Dr. Chris Harvey Clark explores the increased number of white shark observations in Canadian waters.

A never-before-lived-in mansion in Whistler is on the market for $17.9 million – with the listing describing it as a 'steal for the international buyer' due to the current exchange rate, which puts the price in U.S. dollars at $13.1 million.

Irish singer Niall Horan had to ditch his car and walk to Scotiabank Arena where his concert was being held last weekend because the traffic was 'too bad' downtown.

A rave at the Ontario Science Centre was the place where Greg LeBlanc says his relationship first began with his husband Mark in 1997.